[Retracted] Effect of PARP Inhibitor Combined with Bevacizumab on Platinum-Resistant Recurrent Ovarian Epithelial Carcinoma

Table 2

Comparison of clinical efficacy between the two groups [cases (%)].

Group	CR	PR	SD	PD	ORR	DCR
Observation group ()	2 (4.76)	27 (64.29)	8 (19.05)	5 (11.90)	29 (69.05)	37 (88.10)
Control group ()	1 (2.38)	16 (38.10)	11 (26.19)	14 (33.33)	17 (40.48)	28 (66.67)
					6.920	5.509
					0.009	0.019